Illusions, by Richard Bach (Book Review) - Ep 681

Dr. Reedy addresses the two main tasks of intimacy – sharing and listening. He talks about the capacity required to deeply hear and listen to another. He explains that talking tends to be a taking thing and listening requires healing and significant capacity. Hosted on Acast. See acast.com/privacy for more information.

Dr. Reedy discuss the impact of family of orange roles and rules on our psyche. He talks about how we can repair wounds and trauma we experienced. He emphasized the need for overt and explicit communication rather than covert and implicit messaging. He explains how therapy, sitting with a different perspective, can shift the ideas we have sometimes unconsciously internalized. Hosted on Acast. See acast.com/privacy for more information.

Dr. Reedy explores various therapy approaches and how they view symptoms. He explains that symptoms are messengers from the unconscious, the inner-child, and authentic self. We learn to be in dialogue with our symptoms. We can learn to listen rather suppress. As Marcus Aurelius says, “What stands in the way is the way.” Or as Rumi wrote, “The cure for the pain is in the pain.” Hosted on Acast. See acast.com/privacy for more information.

Dr. Reedy discusses how we can understand our experience through using what therapists refer to as “parts work.” From the Ancient Greeks to the present, people have used stories, characters, and archetypes to better understand and work with the different energies that motivate human behavior. These methods, including the most recent iteration, Internal Family Systems, offer a non-shaming perspective where we learn to be in dialogue with ourselves and our parts rather than trying to suppress aspects of the self. Hosted on Acast. See acast.com/privacy for more information.

Dr. Reedy discusses the relationship between guilt, resentment, and boundaries. Hosted on Acast. See acast.com/privacy for more information.

Dr. Reedy reviews the book by Richard Bach, the author of Jonathon Livingston Seagull. Illusions is the allegory of a “Master Messiah” as he passes his wisdom on to Richard, the apprentice. The overarching message of the book is that we are accountable and responsibility for our own meaning, our own happiness. His telling illustrates that such a message is often rejected because we don’t want to take on the responsibility for our lives – we want to blame our unhappiness on our circumstances, on others. Hosted on Acast. See acast.com/privacy for more information.

My Child’s Resentment About Treatment - Ep 680 by Dr. Brad Reedy Hosted on Acast. See acast.com/privacy for more information.

Which Type of Therapy (Individual, Couple, or Family) is Right for Me? - Ep 679 by Dr. Brad Reedy Hosted on Acast. See acast.com/privacy for more information.

#MentalHealthMatters #HealthyRelationships #ParentingSupport #AddictionRecovery #EmotionalWellness #MindfulParenting #TraumaInformed #SelfCareJourney #RelationshipAdvice #PsychologicalSafety #HealingJourney #FamilyDynamics #MentalHealthAwareness #OvercomingAnxiety #BreakTheStigma #PersonalGrowth #MindBodyConnection #WellnessWarrior #LifeCoaching #ResilienceBuilding Hosted on Acast. See acast.com/privacy for more information.

Dr. Reedy welcomes Dr. Alexa Altman where she discusses how psychedelics bring the unconscious material into consciousness. She talks about the importance of integration. Dr. Altman’s Website: https://www.i-psychedelic.com 1. Single-dose psilocybin (25 mg) with psychological support for MDDJAMA – “Single-Dose Psilocybin Treatment for Major Depressive Disorder” psychiatryonline.org+15sunstonetherapies.com+15pmc.ncbi.nlm.nih.gov+15 Summary: Demonstrated strong antidepressant effects and good tolerability over follow-up. Email: [email protected] 2. One-Year Follow-Up of Psilocybin for DepressionStudy: Long-term effects of psilocybin therapy for depressionJohns Hopkins – “Psilocybin treatment for major depression effective for up to a year” Summary: 67% of participants remained in remission one year post-treatment.3. MDMA-Assisted Therapy for Severe PTSDRandomized, placebo-controlled MDMA-assisted therapyNature Medicine – “MDMA-assisted therapy for severe PTSD” Summary: Significant reduction in PTSD symptoms, well‑tolerated in a diverse cohort.Contact (MAPS / Lykos Therapeutics): Email: [email protected] 4. Psilocybin for Cancer-Related Anxiety & DepressionPsilocybin in patients with life-threatening cancerPMC – “High-dose psilocybin produced large decreases in depressed mood and anxiety…” Summary: 80% of participants maintained significant symptom relief at 6 months. Website: heffter.org (contact via site) en.wikipedia.org 1. Johns Hopkins UniversityCenter for Psychedelic and Consciousness ResearchPsilocybin for depression, anxiety, addiction, and end-of-life distressWhy it’s top-tier: The first major U.S. institution to receive regulatory approval for psychedelic research in modern times. 🔗 hopkinspsychedelic.org 2. Imperial College LondonCentre for Psychedelic ResearchPsilocybin for treatment-resistant depression, brain imaging, DMT studiesWhy it’s top-tier: Home of pioneering neuroimaging studies on psychedelics; led by Robin Carhart-Harris (now at UCSF). 🔗 imperial.ac.uk 3. Multidisciplinary Association for Psychedelic Studies (MAPS)MDMA for PTSD (now in Phase 3 trials), harm reduction, global educationWhy it’s top-tier: MAPS initiated the first FDA-approved Phase 3 trials for MDMA-assisted therapy. 🔗 maps.org4. University of California, San Francisco Psychedelic Research Program Psilocybin, DMT, ibogaine; Robin Carhart-Harris now leads U.S. armWhy it’s top-tier: Integrates neuroscience, clinical psychology, and pharmacology. 🔗 psychedelics.ucsf.edu5. NYU Langone HealthCenter for Psychedelic MedicineEnd-of-life anxiety, alcoholism, PTSD, and psilocybin studiesWhy it’s top-tier: Known for rigorous clinical trials and major collaborations. 🔗 med.nyu.edu6. University of California, Los AngelesUCLA Psychedelic Studies InitiativePsilocybin + CBT, anxiety, clinical protocolsWhy it’s top-tier: Conducting one of the few FDA-regulated psilocybin trials with integrated therapy. 🔗 uclapsi.org7. University of Wisconsin–Madison / Usona InstitutePsilocybin for major depression (FDA Phase 3 trials)Why it’s top-tier: Leading U.S.-based nonprofit with regulatory traction and major academic partnerships. 🔗 usonainstitute.org8. Massachusetts General Hospital / Harvard Medical SchoolCenter for the Neuroscience of PsychedelicsNeurobiological mechanisms of psychedelicsWhy it’s top-tier: Combines Harvard academic leadership with Mass General clinical infrastructure. 🔗 massgeneral.org9. University of New MexicoPsychedelic-Assisted Therapies & Research GroupKetamine, DMT, and MDMA research; Indigenous-informed approachesWhy it’s top-tier: Interdisciplinary and trauma-informed program with cultural awareness. 🔗 hsc.unm.edu10. Oregon Health & Science University State-licensed psilocybin therapy programs, public health, trainingWhy it’s top-tier: One of the first institutions engaging with psilocybin therapy post-legalization under Measure 109. 🔗 ohsu.edu Hosted on Acast. See acast.com/privacy for more information.